Repeated inhalation of sevoflurane inhibits airway inflammation in an OVA-induced mouse model of allergic airway inflammation.
OBJECTIVE
Repeated inhalation of sevoflurane (SVF) can benefit asthmatic patients by bronchodilation. However, the impact of repeated inhalation of SVF on allergic airway inflammation has not been clarified. This study was aimed at investigating the effects of repeated inhalation of SVF on airway inflammation in mice.


METHODS
Female C57BL/6 mice were sensitized with ovalbumin (OVA) and treated by inhalation with SVF or vehicle daily for seven consecutive days, immediately followed by OVA challenge. Airway inflammation was evaluated by counting the numbers of different types of inflammatory infiltrates in bronchoalveolar lavage fluid (BALF), histology, cytokine measurements and mucus production in individual mice.


RESULTS
In comparison with the OVA group, repeated inhalation of SVF significantly reduced the numbers of total cells, eosinophils, lymphocytes, macrophages and neutrophils (P < 0.05 to P < 0.01), and the levels of BALF tumour necrosis factor-α and lung high-mobility group box 1 (P < 0.01), accompanied by elevated levels of BALF interleukin-10 in allergic mice (P < 0.05). Repeat inhalation of SVF decreased the levels of serum OVA-specific immunoglobulin E (IgE) and mitigated allergic airway epithelial goblet cell hyperplasia and mucus hypersecretion in allergic mice (P < 0.01).


CONCLUSIONS
Repeated inhalation of SVF inhibits allergic airway inflammation by reducing inflammatory infiltrates, improving the imbalance of cytokine responses and mitigating allergen-specific IgE responses and goblet cell hyperplasia in mice.
Department of Pulmonary, Anhui Geriatric Institute, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China; Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Qi-Ying
QY
Shen
Lei
L
Fang
Hui-Mei
HM
Wu
Fang
F
He
Pei-Shan
PS
Ding
Rong-Yu
RY
Liu
D000818:Animals; D001249:Asthma / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004804:Eosinophils; D005260:Female; D020397:Goblet Cells / Q000473:pathology*; D024243:HMGB1 Protein / Q000032:analysis; D006965:Hyperplasia / Q000473:pathology; D007073:Immunoglobulin E / Q000097:blood; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy; D016753:Interleukin-10 / Q000032:analysis; D008168:Lung / Q000473:pathology*; D018655:Lymphocyte Count; D008264:Macrophages; D008738:Methyl Ethers / Q000008:administration & dosage*; D051379:Mice; D008810:Mice, Inbred C57BL; D009093:Mucus / Q000187:drug effects / Q000378:metabolism; D009504:Neutrophils; D010047:Ovalbumin; D000077149:Sevoflurane; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D001993:Bronchodilator Agents; D024243:HMGB1 Protein; D008738:Methyl Ethers; C439524:TNF protein, human; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D007073:Immunoglobulin E; D000077149:Sevoflurane; D010047:Ovalbumin
allergen; high-mobility group box 1; inflammation; inhalational anaesthetic; sevoflurane